A fusion protein consisting of an anti-PD-L1 antibody fused to the extracellular domain of TGF-β receptor II, M7824, showed excellent pre-clinical activity, suppressing metastases, inducing long-term anti-tumor immunity and improving OS in mouse models of breast and colon cancer, both as a single agent and in combination with a therapeutic cancer vaccine [88,89]. Here, CD274 is linked to cancer.